Hans Briem

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

R.C. Hillig, Brice Sautier, Jens Schroeder et al. · Proceedings of the National Academy of Sciences · 2019 · 379 citations · Full text

Medicine, Molecular Biology, Oncology +17

Efficient multi-objective molecular optimization in a continuous latent space

Robin Winter, Floriane Montanari, Andreas Steffen et al. · Chemical Science · 2019 · 279 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacokinetics +17

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking, Arne Scholz, Philip Lienau et al. · ChemMedChem · 2017 · 184 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (<i>R</i>)‐<i>S</i>‐Cyclopropyl‐<i>S</i>‐(4‐{[4‐{[(1<i>R</i>,2<i>R</i>)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

Ulrich Lücking, Rolf Jautelat, Martin Krüger et al. · ChemMedChem · 2013 · 178 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14

Substantial improvements in large-scale redocking and screening using the novel HYDE scoring function

Nadine Schneider, Sally Hindle, Gudrun Lange et al. · Journal of Computer-Aided Molecular Design · 2011 · 149 citations

Life Sciences, Bioinformatics, Molecular Biology +9